335 related articles for article (PubMed ID: 11226006)
1. Rituximab: an insider's historical perspective.
Grillo-López AJ
Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
[TBL] [Abstract][Full Text] [Related]
2. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: ongoing and future clinical development.
Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and phase I and II trials of rituximab.
Maloney DG
Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
9. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Smith MR
Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy sensitization by rituximab: experimental and clinical evidence.
Wilson WH
Semin Oncol; 2000 Dec; 27(6 Suppl 12):30-6. PubMed ID: 11225998
[TBL] [Abstract][Full Text] [Related]
11. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
12. High-dose rituximab therapy in chronic lymphocytic leukemia.
Keating M; O'Brien S
Semin Oncol; 2000 Dec; 27(6 Suppl 12):86-90. PubMed ID: 11226005
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in indolent lymphoma: the single-agent pivotal trial.
McLaughlin P; Hagemeister FB; Grillo-López AJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled antibody therapy of B-cell lymphomas.
Press OW
Semin Oncol; 1999 Oct; 26(5 Suppl 14):58-65. PubMed ID: 10561019
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
17. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
20. FDA approves new kind of lymphoma treatment. Food and Drug Administration.
James JS; Dubs G
AIDS Treat News; 1997 Dec; (No 284):2-3. PubMed ID: 11364912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]